期刊文献+

Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis 被引量:3

Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis
下载PDF
导出
摘要 AIM: To establish the prevalence of liver fibrosis and to evaluate the possible risk factors for fibrosis and progression in Asian with psoriasis treated with methotrexate (MTX) based on liver histology. METHODS: Patients with psoriasis treated with MTX referred to the Department of Gastroenterology, Tan Tock Seng Hospital for liver biopsy were identified and retrospectively studied. Patient case notes and electronic records were retrieved from the hospital database and relevant data collated. Histological changes of liver biopsies were staged according to Roengik score. The factors assessed were age, gender, ethnicity, cumulative dose of MTX, presence of comorbid conditions such as diabetes, hypertension, hyperlipidemia, and ethanol use. We also assessed the histological change in those with multiple liver biopsies. Statistical analysis was performed using Stata V.9.2. RESULTS: There were altogether 59 patients (median age 50 years old, range 22-81 years old, male, 88%) with 98 biopsies liver biopsies; 6 normal [median cumulative dose (MCD), 2285 mg]; 62 gradeⅠ (MCD 2885 mg), 23 grade Ⅱ (MCD 1800 mg) and 7 grade Ⅲ (MCD 1500 mg). There was no grade Ⅳ or cirrhosis. The prevalence of liver fibrosis (grade Ⅲ) was 12%. Of the factors assessed, diabetes (P=0.001) and hypertension (P=0.003) were significant for fibrosis on univariate analysis but not on multivariate analysis. Of the 26 patients who had more than one biopsy (median 2, range 2-6), 57.7% (n=15) were stable, 34.6% (n=9) had progression and 7.7% (n=2) had regression of histological grades. On univariate analysis, nonChinese ethnicity (P=0.031), diabetes (P=0.018), and hyperlipidemia (P=0.011) were predictive of progression of grades, but these were not significant on multivariate analysis. CONCLUSION: Liver fibrosis in Asian psoriatic population on MTX is comparable to the West. Cumulative dose was not associated with liver fibrosis. Metabolic syndrome is important factors. AIM: To establish the prevalence of liver fibrosis and to evaluate the possible risk factors for fibrosis and progression in Asian with psoriasis treated with methotrexate (MTX) based on liver histology. METHODS: Patients with psoriasis treated with MTX referred to the Department of Gastroenterology, Tan Tock Seng Hospital for liver biopsy were identified and retrospectively studied. Patient case notes and electronic records were retrieved from the hospital database and relevant data collated. Histological changes of liver biopsies were staged according to Roengik score. The factors assessed were age, gender, ethnicity, cumulative dose of MTX, presence of comorbid conditions such as diabetes, hypertension, hyperlipidemia, and ethanol use. We also assessed the histological change in those with multiple liver biopsies. Statistical analysis was performed using Stata V.9.2. RESULTS: There were altogether 59 patients (median age 50 years old, range 22-81 years old, male, 88%) with 98 biopsies liver biopsies; 6 normal [median cumulative dose (MCD), 2285 mg]; 62 gradeⅠ (MCD 2885 mg), 23 grade Ⅱ (MCD 1800 mg) and 7 grade Ⅲ (MCD 1500 mg). There was no grade Ⅳ or cirrhosis. The prevalence of liver fibrosis (grade Ⅲ) was 12%. Of the factors assessed, diabetes (P=0.001) and hypertension (P=0.003) were significant for fibrosis on univariate analysis but not on multivariate analysis. Of the 26 patients who had more than one biopsy (median 2, range 2-6), 57.7% (n=15) were stable, 34.6% (n=9) had progression and 7.7% (n=2) had regression of histological grades. On univariate analysis, nonChinese ethnicity (P=0.031), diabetes (P=0.018), and hyperlipidemia (P=0.011) were predictive of progression of grades, but these were not significant on multivariate analysis. CONCLUSION: Liver fibrosis in Asian psoriatic population on MTX is comparable to the West. Cumulative dose was not associated with liver fibrosis. Metabolic syndrome is important factors.
出处 《World Journal of Hepatology》 CAS 2013年第5期275-280,共6页 世界肝病学杂志(英文版)(电子版)
关键词 HEPATOTOXICITY Liver FIBROSIS METHOTREXATE Risk factors CIRRHOSIS Hepatotoxicity Liver fibrosis Methotrexate Risk factors Cirrhosis
  • 相关文献

参考文献28

  • 1Berends MA,Snoek J,de Jong EM,van de Kerkhof PC,van Oijen MG,van Krieken JH,Drenth JP.Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Alimentary Pharmacology and Therapeutics . 2006
  • 2Zachariae H.Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies. Dermatology . 2005
  • 3Roenigk HH Jr,Auerbach R,Maibach H,Weinstein G,Lebwohl M.Methotrexate in psoriasis:consensus confer-ence. Journal of the American Academy of Dermatology . 1998
  • 4Zachariae H.Liver biopsies and methotrexate:a time for reconsideration. J American Academy of Dermatology . 2000
  • 5Aithal GP,Haugk B,Das S,Card T,Burt AD,Record CO.Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified. Alimentary Pharmacology and Therapeutics . 2004
  • 6Boffa MJ,Chalmers RJ,Haboubi NY,et al.Sequential liver biopsies during long-term methotrexate treatment for psoriasis:a reappraisal. Br J Dermatol . 1995
  • 7G Langman,PM Hall,G Todd.Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. Journal of Gastroenterology . 2001
  • 8Ong JP,Younossi ZM.Epridemiology and natural history of NAFLDand NASH. Clinics in Liver Disease . 2007
  • 9Zachariae H,Sogaard H,Heickendorff L.Methotrexate-induced liver cirrhosis.Clinical,histological and serological studies—a further 10-year follow-up. Dermatology . 1996
  • 10Ng LC,Lee YY,Lee CK,Wong SM.A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. International Journal of Dermatology . 2013

同被引文献10

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部